Cardiovascular drugs and cancer: Of competing risk, smallpox, Bernoulli, and d'Alembert

European Heart Journal

Volumn 34, Issue 15, 2013, Pages 1095-1098

  Messerli, Franz H ^a   Bangalore, Sripal ^b   Torp Pedersen, Christian ^c   Staessen, Jan A ^d,e   Kostis, John B ^f  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CANCER MORTALITY; CANCER RISK; CARCINOGENICITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CORONARY ARTERY DISEASE; DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; LIFE EXPECTANCY; LONG TERM CARE; LUNG CANCER; NEOPLASM; PNEUMONIA; PRIORITY JOURNAL; PSEUDOTUMOR; RISK ASSESSMENT; SMALLPOX; SMOKING CESSATION; STATISTICAL SIGNIFICANCE; SYSTOLIC HYPERTENSION;

ANTINEOPLASTIC AGENTS; CARCINOGENS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HISTORY, 18TH CENTURY; HUMANS; LIFE EXPECTANCY; NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SMALLPOX; SMOKING CESSATION;

EID: 84876576721     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs158     Document Type: Article

References (33)

1. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomized controlled trials. Lancet Oncol 2010;11:627-636.
2. Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, Gupta AK, Sever PS, Gluud C, Messerli FH. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomized trials. Lancet Oncol 2011;12:65-82.
3. The ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals. J Hypertens 2011;29:623-635.
4. Pasternak B, Svanström H, Callréus T, Melbye M, Hviid A. Use of Angiotensin receptor blockers and the risk of cancer. Circulation 2011;123:1729-1736.
5. Lindholm LH, Carlberg B. Blood-pressure drugs and cancer: much ado about nothing? Lancet Oncol 2011;12:6-8.
6. U.S. Food and Drug Administration. FDA Drug Safety Communication: no increase in risk of cancer with certain blood pressure drugs-angiotensin receptor blockers (ARBs). 2 June 2011.
7. Bernoulli D. Essai d'une nouvelle analyse de la mortalite causee par la petite verole. Mem Math Phys Acad Roy Sci, Paris (1766) 1.
8. Bouckaert LP, van der Waerden BL (eds.), Die Werke von Daniel Bernoulli, Bd. 2 Analysis und Wahrscheinlichkeitrechnung. Basel: Birkhauser, 1982, p235.
9. Haley E. An estimate of the degrees of the mortality of mankind, drawn from curious tables of the births and funerals at the city of Breslaw;with an attempt to ascertain the price of annuities upon lives. Philos Trans 17(1693) 596.
10. (Reprinted in J. Inst. Actuaries 18 (1874) 251 and in facsimile 112 (1985) 278.
11. Bernoulli D. Reflexions sur les avantages de l'inoculation. Mercure de France 1760:173.
12. Bouckaert LP, van der Waerden BL (eds.), Die Werke von Daniel Bernoulli, Bd. 2 Analysis und Wahrscheinlichkeitsrechnung. Basel: Birkhauser, 1982, p. 268).
13. d'Alembert J. le R. Sur l'application du calcul des probabilities a l'inoculation de la petite verole. In: d'Alembert J. le R. (ed.), Opuscules Mathematiques t. 2. Paris: David;1761, p26.
14. Daston L. Classical Probability in the Enlightenment. NJ: Princeton University Press;1980.
15. Torp-Pedersen C, Køber L. Prolongation of life with angiotensin converting enzyme inhibitor therapy. Eur Heart J 2000;21:597-598. (Pubitemid 30168806)
16. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials. BMJ 2009;338:b2376.
17. Torp-Pedersen C, Køber L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999;354:9-12. (Pubitemid 29304295)
18. Kostis JB, Cabrera J, Cheng JQ, Cosgrove NM, Deng Y, Pressel SL, Davis BR. Association between chlorthalidone treatment of systolic hypertension and longterm survival. JAMA 2011;306:2588-2593.
19. Diamond GA, Kaul S. From here to eternity: a unified kinetic model for the pathophysiology of atherosclerotic events. Am J Med 2007;120:5-11. (Pubitemid 46026978)
20. Heron M. Division of vital statistics. Deaths: leading causes for 2006. Natl Vital Stat Rep 2010;58:1-100.
21. Kostis WJ, Deng Y, Pantazopoulos JS, Moreyra AE, Kostis JB;for the Myocardial Infarction Data Acquisition system (MIDAS 14) Study Group. Trends in mortality of acute myocardial infarction after discharge from the hospital. Circ Cardiovasc Qual Outcomes 2010;3:581-589.
22. American Heart Association. Heart Disease and Stroke Statistics-2006 Update. http://americanheart.org/downloadable/heart/113535864858055-1026-HS- Stats 06book.pdf.
23. Leading Causes of Death (2008). Statistics Canada. http://www.statcan.gc. ca (13 January 2012).
24. Buch P, Rasmussen S, Abildstrom SZ, Køber L, Carlsen J, Torp-Pedersen C;TRACE investigators. The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years. Eur Heart J 2005;26:145-152. (Pubitemid 40282782)
25. Surveillance Epidemiology and End Results. http://seer.cancer.gov/csr/ 1975-2007/browse-csr.php?section=2&page=sect-02-table.08.html (12 July 2011).
26. Grossman E, Messerli FH. Drug induced hypertension-an unappreciated cause of secondary hypertension. Am J Med 2012;125:14-22.
27. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010;102:14-25.
28. Smoking-attributable mortality, years of potential life lost, and productivity losses-United States, 2000-2004. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep 2008;57:1226-1228.
29. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2004;CD003041.
30. Shah AM, Pfeffer MA, Hartley LH, MoyéLA, Gersh BJ, Rutherford JD, Lamas GA, Rouleau JL, Braunwald E, Solomon SD. Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction. Am J Cardiol 2010;106:911-916.
31. Peto J. That lung cancer incidence falls in ex-smokers: misconceptions 2. Br J Cancer 2011;104:389.
32. Huncharek M, Haddock KS, Reid R, Kupelnick B. Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. Am J Public Health 2010;100:693-701.
33. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg 2008;393: 535-545.